Physician profile
Raphael L Lopez
NPI 1932177177
$8,847.14
in general payments reported to CMS, 2019-2025
42 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,425 · 2020: $2,329 · 2021: $2,364 · 2022: $888 · 2023: $769 · 2024: $717 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,134.06 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,033.58 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $931.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $603.34 | 2019-2025 | Repatha, Repatha, Otezla |
| Allergan, INC. | $579.30 | 2019-2020 | |
| Abbvie INC. | $562.09 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.97 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $324.41 | 2019-2024 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $323.95 | 2019-2021 | |
| Pfizer INC. | $279.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $261.23 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $208.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $177.59 | 2019-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Otsuka America Pharmaceutical, INC. | $176.05 | 2022-2023 | Rexulti |
| Stryker Corporation | $173.99 | 2024 | Alphavent |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.